167 related articles for article (PubMed ID: 9625540)
1. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck.
Bier H; Hoffmann T; Haas I; van Lierop A
Cancer Immunol Immunother; 1998 May; 46(3):167-73. PubMed ID: 9625540
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
3. Natural killer (NK) cells as effectors of antibody-dependent cytotoxicity with chimeric antibodies reactive with human squamous-cell carcinomas of the head and neck.
Sung MW; Yasumura S; Johnson JT; Van Dongen GA; Whiteside TL
Int J Cancer; 1995 Jun; 61(6):864-72. PubMed ID: 7790123
[TBL] [Abstract][Full Text] [Related]
4. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.
López-Albaitero A; Lee SC; Morgan S; Grandis JR; Gooding WE; Ferrone S; Ferris RL
Cancer Immunol Immunother; 2009 Nov; 58(11):1853-64. PubMed ID: 19319529
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma.
Kawaguchi Y; Kono K; Mimura K; Sugai H; Akaike H; Fujii H
Int J Cancer; 2007 Feb; 120(4):781-7. PubMed ID: 17096332
[TBL] [Abstract][Full Text] [Related]
6. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.
Taylor RJ; Chan SL; Wood A; Voskens CJ; Wolf JS; Lin W; Chapoval A; Schulze DH; Tian G; Strome SE
Cancer Immunol Immunother; 2009 Jul; 58(7):997-1006. PubMed ID: 18979096
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of interferon-gamma on squamous-cell carcinoma of head and neck targets in antibody-dependent cellular cytotoxicity mediated by human natural killer cells.
Sung MW; Johnson JT; Van Dongen G; Whiteside TL
Int J Cancer; 1996 May; 66(3):393-9. PubMed ID: 8621263
[TBL] [Abstract][Full Text] [Related]
8. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.
Hoffmann T; Hafner D; Ballo H; Haas I; Bier H
Anticancer Res; 1997; 17(6D):4419-25. PubMed ID: 9494544
[TBL] [Abstract][Full Text] [Related]
10. The role of apoptosis in antibody-dependent cell-mediated cytotoxicity against monolayers of human squamous cell carcinoma of the head and neck targets.
Sung MW; Nagashima S; Johnson JT; Van Dongen GA; Whiteside TL
Cell Immunol; 1996 Jul; 171(1):20-9. PubMed ID: 8660833
[TBL] [Abstract][Full Text] [Related]
11. Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.
Friedman J; Padget M; Lee J; Schlom J; Hodge J; Allen C
Oral Oncol; 2019 Mar; 90():38-44. PubMed ID: 30846174
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
Baysal H; De Pauw I; Zaryouh H; De Waele J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; Jacobs J; Wouters A
Br J Cancer; 2020 Sep; 123(5):752-761. PubMed ID: 32541873
[TBL] [Abstract][Full Text] [Related]
13. An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.
Temam S; Spicer J; Farzaneh F; Soria JC; Oppenheim D; McGurk M; Hollebecque A; Sarini J; Hussain K; Soehrman Brossard S; Manenti L; Evers S; Delmar P; Di Scala L; Mancao C; Feuerhake F; Andries L; Ott MG; Passioukov A; Delord JP
Ann Oncol; 2017 Nov; 28(11):2827-2835. PubMed ID: 28950289
[TBL] [Abstract][Full Text] [Related]
14. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer.
López-Albaitero A; Ferris RL
Arch Otolaryngol Head Neck Surg; 2007 Dec; 133(12):1277-81. PubMed ID: 18086972
[TBL] [Abstract][Full Text] [Related]
15. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
[TBL] [Abstract][Full Text] [Related]
16. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
[TBL] [Abstract][Full Text] [Related]
17. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.
Modjtahedi H; Moscatello DK; Box G; Green M; Shotton C; Lamb DJ; Reynolds LJ; Wong AJ; Dean C; Thomas H; Eccles S
Int J Cancer; 2003 Jun; 105(2):273-80. PubMed ID: 12673691
[TBL] [Abstract][Full Text] [Related]
18. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.
Modjtahedi H; Hickish T; Nicolson M; Moore J; Styles J; Eccles S; Jackson E; Salter J; Sloane J; Spencer L; Priest K; Smith I; Dean C; Gore M
Br J Cancer; 1996 Jan; 73(2):228-35. PubMed ID: 8546911
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Correale P; Marra M; Remondo C; Migali C; Misso G; Arcuri FP; Del Vecchio MT; Carducci A; Loiacono L; Tassone P; Abbruzzese A; Tagliaferri P; Caraglia M
Eur J Cancer; 2010 Jun; 46(9):1703-11. PubMed ID: 20399639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]